This review explains how glucose scarcity, lipid disruption, amino acid deprivation, and toxic metabolites weaken CAR-T cells ...

This review examines how CAR-T cell therapy is expanding beyond blood cancers into solid tumors, autoimmune diseases, chronic ...

At AACR, first‑in‑human KIR‑CAR T data show early activity in solid tumors and introduce a novel design aimed at limiting T ...

A new clinical trial is enrolling up to 60 children and young people with solid tumors across the United States and United ...

CAR T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for more than 85% of all cancers. Columbia University ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the ...

Prefer Newsweek on Google to see more of our trusted coverage when you search. Cancer remains one of the greatest challenges in modern medicine. While advances in surgery, targeted therapy and ...

Creative Biolabs is accelerating CAR‑T innovation, driving breakthroughs in solid tumor targeting. SHIRLEY, NY, UNITED STATES, February 13, 2026 / EINPresswire.com / — The global CAR‑T therapy ...

Jointly developed by China Medical University Hospital and Ever Supreme Bio Technology, the platform demonstrates compelling preclinical tumor clearance across multiple models TAICHUNG, Feb. 13, 2026 ...

The therapy, known as satri-cel (CT041), is the world's first CAR-T treatment specifically developed for solid tumors targeting Claudin18.2, a biomarker commonly found in gastric (stomach) and ...

CAR-T cell therapy works well in blood cancers, but many patients still become resistant. A key reason is the presence of CAR ...